Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with ...
Dec 11, 2017
0
0
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for ...
Nov 22, 2017
0
0
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell ...
Oct 23, 2017
0
0
A group of international cancer researchers led by investigators from Mayo Clinic and University of New South Wales Sydney has found that the level of a type of white blood cell, called tumor-infiltrating lymphocytes, present ...
Oct 12, 2017
0
90
(HealthDay)—Response to immunosuppressive therapy (IST) predicts overall survival (OS) in aplastic anemia (AA), according to a study published online Aug. 29 in the American Journal of Hematology.
Sep 7, 2017
0
0
(HealthDay)—There has been a significant decline in the risk of secondary cancers after Kaposi sarcoma (KS) in the era of highly-active antiretroviral therapy (HAART), according to a study published online Aug. 24 in JAMA ...
Aug 25, 2017
0
1
How do initially benign forms of cancer evolve to become aggressive? In a quest to answer this long-standing question, an EU project has studied the growth and clonal evolution of chronic lymphocytic leukaemia (CLL)—a blood ...
Aug 11, 2017
0
0
Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses. As a result, insights gained in the lab may be ...
Jul 26, 2017
0
22
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept ...
Jun 28, 2017
0
4
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new ...
May 31, 2017
0
0
